Back

SGLT2 inhibitors improve cardiovascular clinical outcomes in patients undergoing anthracycline chemotherapy: a systematic review and meta-analysis of 13,333 patients.

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: SGLT2 inhibitors in heart failure: prevention and treatment Cardiotoxicity of Drugs and Other Therapies ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Luigi Spadafora

Sapienza University of Rome, Latina (Italy)

3 More presentations in this session

Presentation thumbnail
Right vs. left cardiac function and structure: impact of SGLT2i in acute decompensate heart failure with central sleep apnea
Assistant Professor P. Kalaydzhiev (Sofia, BG)
Abstract Slides Video
Presentation thumbnail
Two years follow-up of use of SGLT2 inhibitors in HFrEF patients hospitalized for decompensation
Associate Professor V. Vintila (Bucharest, RO)
Abstract Slides Video
Presentation thumbnail
THRV-1268, a novel and potent SGK1 inhibitor, improved adverse cardiac remodeling beyond empagliflozin, an SGLT2 inhibitor, by reducing inflammation and fibrosis mechanisms in heart failure.
Doctor S. Das (Boston, US)
Slides Video

Access the full session

Session thumbnail
SGLT2 inhibitors in heart failure: prevention and treatment

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Anthracycline cardiotoxicity in patients receiving sodium-glucose co-transporter-2 inhibitors -is there any difference?
thumbnail
Congress Presentation
SGLT2 inhibitors and cardiotoxicity in diabetic patients receiving anthracycline therapy: a retrospective study
thumbnail
Congress Presentation
Sodium-glucose co-transporter-2 inhibitors : a potential cardioprotective agent?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources